Overview

LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Status:
Completed

Trial end date:
2017-07-01

Target enrollment:

Participant gender:

Summary

Loteprednol Etabonate Ophthalmic Gel, (BID and TID) versus Vehicle Group for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.

Phase:

Phase 3

Details

Lead Sponsor:

Bausch & Lomb Incorporated
Valeant Pharmaceuticals International, Inc.

Treatments:

Loteprednol Etabonate